TEAM
Our Culture
Our people are the core of everything we will accomplish. We are united in our mission to improve patient lives by pushing the scientific boundaries of covalent medicines. Our Hyku community is composed of diverse individuals that hold respect, collaboration and innovation central to our efforts.
Scientific Founder
Ku-Lung (Ken) Hsu, PhD
Endowed Associate Professor of Chemistry
CPRIT Scholar
The University of Texas at Austin
Board of Directors
Laura Brass, PhD
Managing Director
Novartis Venture Fund
Kleem Chaudhary, PhD
President & CEO
Hyku Biosciences
Laura Tadvalkar, PhD
Managing Director
RA Capital Management
Matthias Van Woensel, PhD
Partner
Droia Ventures
Board Observers
Adam Cotton, PhD
Analyst
Novartis Venture Fund
Rindert Missiaen, PhD
Associate
Droia Ventures
Jonathan Pritz, PhD
Analyst
RA Capital Management
Kou Qin, PhD
Managing Director
Eisai Innovation
Min Shin, PharmD
Director
KB Investment
Anna Turetsky, PhD
Principal, Venture Investments
The Mark Foundation for Cancer Research